MenAfriVac is a vaccine developed for use in sub-Saharan Africa for children and adults between 9 months and 29 years of age against meningococcal bacterium Neisseria meningitidis group A. The vaccine costs less than US$0.50 per dose.[1][2]
^World Health Organization (November 2011). "Meningococcal vaccines. World Health Organization position paper, November 2011" (PDF). World Health Organization. Retrieved 31 January 2017.
^World Health Organization (February 2015). "Meningococcal A conjugate vaccine: updated guidance. World Health Organization" (PDF). World Health Organization. Retrieved 31 January 2017.
MenAfriVac is a vaccine developed for use in sub-Saharan Africa for children and adults between 9 months and 29 years of age against meningococcal bacterium...
trivalent A/C/W135 polysaccharide vaccines, though the introduction of MenAfriVac (meningococcus group A vaccine) has demonstrated effectiveness in young...
In 2010, the Meningitis Vaccine Project introduced a vaccine called MenAfriVac in the African meningitis belt. It was made by generic drug maker Serum...
for children 6 weeks of age through 18 months of age. A vaccine called MenAfriVac has been developed through a program called the Meningitis Vaccine Project...
belt. In June 2010 various sources announced that they had developed MenAfriVac, which is an inexpensive, safe, and highly effective vaccine which is...
(NmA). However, a monovalent serogroup A meningococcal conjugate vaccine (MenAfriVac) was introduced in the region in 2010. Since then, meningococcal outbreaks...
meningitis vaccine to prevent an emerging epidemic in Africa, known as MenAfriVac, in 2010. She has also worked on communications strategies to promote...
Global Information